The FDA approved combination of<unk>  used with ombitasvir, paritaprevir, and ritonavir in the product Viekira Pak can cause a number of adverse effects. When Viekira Pak was used without ribavirin, nausea, severe itching, and insomnia occurred in more than 5% of the subjects. Less commonly, patients experienced increases in liver enzymes, such as AST and ALT, to greater than five times the upper limit of normal (occurred in 1% of patients). Usually this was asymptomatic. However, this is notable because females who are taking ethinylestradiol are at an increased risk for this side effect (25%).<unk>  could cause hepatitis B re-activation in people co-infected with hepatitis B and C viruses. The European Medicines Agency recommended screening all people for hepatitis B before starting<unk>  for hepatitis C in order to minimize the risk of hepatitis B reactivation.
Dasabuvir
Telaprevir
Fosamprenavir
Coronavir
Sofosbuvir
Abacavir
Enfuvirtide
Indinavir